<DOC>
	<DOCNO>NCT02244827</DOCNO>
	<brief_summary>This study aim compare pharmacokinetics levonadifloxacin sulfate metabolite single dose oral WCK 2349 1000 mg patient hepatic impairment healthy volunteer .</brief_summary>
	<brief_title>Pharmacokinetics WCK 2349 In Patients With Hepatic Impairment</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Body Mass Index ( BMI ) : 18.0 38.0 ( Body weight kg / Height m2 ) , inclusive . Subjects must fulfill follow criterion : Patients hepatic impairment : Considered clinically stable opinion Investigator Patients different degree impair hepatic function assess ChildPugh classification score : mild ( 56 point ) , moderate ( 79 point ) severe ( 1015 point ) impair hepatic function . Documented history cirrhosis diagnose liver biopsy , ultrasonography ( USG ) , compute tomography ( CT ) scan , magnetic resonance imaging ( MRI ) OR Healthy volunteer : Have normal hepatic function Participants history selflimited hepatitis A complete resolution document least 6 month prior entry allow Known hypersensitivity quinolones/fluoroquinolones . Subjects must fulfill follow criterion : In hepatically impaired patient : Use prohibit concomitant medication , exception essential management hepatic impairment treatment concomitant stable medical condition hepatically impaired patient per discretion Investigator . Fluctuating rapidly deteriorate hepatic function indicate recent history widely vary worsen clinical and/or laboratory sign hepatic impairment judge Investigator . Concomitant treatment Interferon prohibit medication Active stage 3 stage 4 encephalopathy OR Healthy Volunteers : Use concomitant medication within 7 day screen except deem safe study Investigator Medical Monitor . History clinically significant chronic and/or active hepatic disease include elevation serum transaminase include aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) [ except consider nonsignificant Investigator ; however , exceed 1.5 time Upper Limit Normal ( ULN ) ] , hepatitis ( Hepatitis A , B C ) , biliary tract disease , history significant gastrointestinal surgery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>